Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 32Triple Negative Breast Neoplasms 26Carcinoma, Transitional Cell 9Neoplasm Metastasis 8Carcinoma, Non-Small-Cell Lung 8Urinary Bladder Neoplasms 7Lung Neoplasms 4Endometrial Neoplasms 3Brain Neoplasms 3Small Cell Lung Carcinoma 2Salivary Gland Neoplasms 2Ovarian Neoplasms 2Advanced Breast Cancer 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urothelial Bladder Carcinoma 1Triple Negative Locally Advanced Non-resectable Breast Cancer 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Recurrence 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm, Residual 1Muscle Invasive Bladder Urothelial Carcinoma 1

Interventions

Injections 20Carboplatin 9pembrolizumab 8Bevacizumab 6Pemetrexed 5Paclitaxel 5Leucovorin 5Fluorouracil 5Docetaxel 5fludarabine 4Oxaliplatin 4Capecitabine 4sotorasib 3atezolizumab 3Drug Therapy 3Cyclophosphamide 3trifluridine tipiracil drug combination 2trametinib 2toripalimab 2spartalizumab 2palbociclib 2olaparib 2Panitumumab 2Nivolumab 2Immune Checkpoint Inhibitors 2Fulvestrant 2Etoposide 2Cisplatin 2Cetuximab 2130-nm albumin-bound paclitaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Solid Tumors × sacituzumab govitecan × 1 year × Clear all
NCT06167317 2026-05-28

Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors

Gilead Sciences

Phase 1 Recruiting
278 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡